Cargando…

The effect of scheduled antibody testing on treatment patterns in interferon-treated patients with multiple sclerosis

BACKGROUND: Many patients with relapsing-remitting multiple sclerosis (MS) treated with high-dose interferon-β (IFNβ) develop serum binding antibodies (BAb) and neutralizing antibodies (NAb). NAb reduces the biological activity of IFNβ, which contributes to clinical failure in these patients. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fox, Edward, Green, Barbara, Markowitz, Clyde, Murray, Ronald, Goodman, Andrew D, Glenski, Stephen J, Loupe, Pippa, Cogburn, Jo Nita
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994206/ https://www.ncbi.nlm.nih.gov/pubmed/24708578 http://dx.doi.org/10.1186/1471-2377-14-73

Ejemplares similares

An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
por: Wolinsky, Jerry S, et al.
Publicado: (2020)

Neutralizing Antibodies Against Interferon-Beta in Korean Patients with Multiple Sclerosis
por: Hyun, Jae-Won, et al.
Publicado: (2018)

Multiple Sclerosis and Other Demyelinating Diseases
por: Soldan, Samantha S., et al.
Publicado: (2008)

Clinical testing for neutralizing antibodies to interferon-β in multiple sclerosis
por: Creeke, Paul I., et al.
Publicado: (2013)

Deficient Phosphorylation of Stat1 in Leukocytes Identifies Neutralizing Antibodies in Multiple Sclerosis Patients Treated with Interferon-Beta
por: Gavasso, Sonia, et al.
Publicado: (2014)

Thrombotic Microangiopathy in Interferon‐beta‐Treated Multiple Sclerosis Patient
por: Malekzadeh, Masoud Mohammad, et al.
Publicado: (2020)

Ocrelizumab reduces progression of upper extremity impairment in patients with primary progressive multiple sclerosis: Findings from the phase III randomized ORATORIO trial
por: Fox, Edward J, et al.
Publicado: (2018)

29 gauge needles improve patient satisfaction over 27 gauge needles for daily glatiramer acetate injections
por: Glenski, Stephen, et al.
Publicado: (2009)

Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies
por: Wallach, Asya I., et al.
Publicado: (2022)

Severity of COVID19 infection among patients with multiple sclerosis treated with interferon-β
por: Simpson-Yap, Steve, et al.
Publicado: (2022)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Beta-interferons in multiple sclerosis
por: Aggarwal, Sourabh, et al.
Publicado: (2010)

Interferon Treatment of Multiple Sclerosis
por: Alajbegovic, Azra, et al.
Publicado: (2012)

Antibodies to Interferon beta in Patients with Multiple Sclerosis Receiving CinnoVex, Rebif, and Betaferon
por: Zare, Nasrin, et al.
Publicado: (2013)

Long-Term Consequences of High Titer Neutralizing Antibodies to Interferon-β in Multiple Sclerosis
por: Dunn, Nicky, et al.
Publicado: (2020)

Age-Adjusted Schedules of Venetoclax and Hypomethylating Agents to Treat Extremely Elderly Patients with Acute Myeloid Leukemia
por: Lee, Aaron M., et al.
Publicado: (2022)

On crushing of deutetrabenazine tablets
por: Knebel, Helena, et al.
Publicado: (2021)

Neutralizing antibodies and fatigue as predictors of low response to interferon-beta treatment in patients with multiple sclerosis
por: Manceau, Philippe, et al.
Publicado: (2014)

Prevalence of neutralising antibodies to interferon-beta and clinical response in Chinese patients with relapsing multiple sclerosis
por: Lau, Alexander Y, et al.
Publicado: (2017)

Baseline Gene Expression Signatures in Monocytes from Multiple Sclerosis Patients Treated with Interferon-beta
por: Bustamante, Marta F., et al.
Publicado: (2013)

Acceptance of the Extracare Program by Beta Interferon-Treated Patients With Multiple Sclerosis: Results of the Explore Study
por: Freidel, Matthias, et al.
Publicado: (2015)

Thrombotic microangiopathy induced by interferon beta in patients with multiple sclerosis: three cases treated with eculizumab
por: Allinovi, Marco, et al.
Publicado: (2017)

Myelin water imaging in relapsing multiple sclerosis treated with ocrelizumab and interferon beta-1a
por: Kolind, Shannon, et al.
Publicado: (2022)

Thyroid Peroxidase Antibodies in Non-Interferon Treated Hepatitis C Patients in Pakistan
por: Shafiq, Muhammad Imtiaz, et al.
Publicado: (2015)

Serum S100B in primary progressive multiple sclerosis patients treated with interferon-beta-1a
por: Lim, Ee Tuan, et al.
Publicado: (2004)

MxA mRNA Quantification and Disability Progression in Interferon Beta-Treated Multiple Sclerosis Patients
por: Serana, Federico, et al.
Publicado: (2014)

An Autopsy Case of Fulminant Hepatitis in a Patient with Multiple Sclerosis Treated by Interferon-Beta-1a
por: Yamazaki, Yuichi, et al.
Publicado: (2017)

Outcomes of COVID-19 among patients treated with subcutaneous interferon beta-1a for multiple sclerosis
por: Freedman, Mark S., et al.
Publicado: (2021)

The Role of Type 1 Interferon in Systemic Sclerosis
por: Wu, Minghua, et al.
Publicado: (2013)

Type I interferon, anti-interferon antibodies, and COVID-19
por: Calabrese, Leonard H, et al.
Publicado: (2021)

Recurrent Duplication and Diversification of Acrosomal Fertilization Proteins in Abalone
por: Carlisle, J. A., et al.
Publicado: (2022)

Pharmacokinetic and Metabolic Profile of Deutetrabenazine (TEV‐50717) Compared With Tetrabenazine in Healthy Volunteers
por: Schneider, Frank, et al.
Publicado: (2020)

Pharmacokinetics of Deutetrabenazine and Tetrabenazine: Dose Proportionality and Food Effect
por: Schneider, Frank, et al.
Publicado: (2020)

The Cost of Relapsing-Remitting Multiple Sclerosis Patients Who Develop Neutralizing Antibodies during Interferon Beta Therapy
por: Paolicelli, Damiano, et al.
Publicado: (2016)

Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis
por: Bachelet, Delphine, et al.
Publicado: (2016)

Cross-reactivity of antibodies against interferon beta in multiple sclerosis patients and interference of the JAK-STAT signaling pathway
por: Hurtado-Guerrero, Isaac, et al.
Publicado: (2017)

Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α
por: Aruna,, et al.
Publicado: (2018)

Laquinimod dampens hyperactive cytokine production in Huntington's disease patient myeloid cells
por: Dobson, Lucianne, et al.
Publicado: (2016)

Fremanezumab for preventive treatment of migraine: Functional status on headache-free days
por: VanderPluym, Juliana, et al.
Publicado: (2018)

Anti-HMGCR antibodies in systemic sclerosis
por: Hudson, Marie, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_e9si3dv7v38mrrprg2d95c037e